Demographics and baseline characteristics.
asthma, diabetes
RECRUITMENT, ASTHMA, CORONAVIRUS, HYPERTENSION, SEVERE ACUTE RESPIRATORY SYNDROME, DIABETES
The study was conducted between February 2021 and October 2021 and closed after completion of recruitment of cohorts A and B, as additional cohorts were not required. Of 143 patients screened, 104 were randomized and 100 were included in the mITTI population (bemnifosbuvir 550 mg, Patient disposition. The mITTI population is defined as all patients that received at least 1 dose of study treatment and had at least 1 positive SARS-CoV-2 RT-PCR test result during the study. The safety population was defined as all patients who received at least 1 dose of study treatment. ITT, intent-to-treat population; mITTI, modified intent-to-treat infected population; RT-PCR, reverse transcription PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.Demographics and baseline characteristics are presented in Demographics and baseline characteristics (pooled placebo, cohorts A, B and cohorts A, B placebo)BMI, body mass index; SD, standard deviation.Including hypertension.Including moderate to severe asthma.Including diabetes.